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ABSTRACT
Objective: The present study was undertaken to study the therapeutic effects of low dose fractionated cranial X-irradiation on reducing the amyloid-
beta (Aβ) induced oxidative stress burden in an animal model of Alzheimer’s disease (AD).
Methods: S.D. female rats received an intracerebroventricular injection of Aβ peptide at stereotaxically defined points. Experimental sessions were 
conducted by randomly dividing animals into four groups, namely sham-operated, Aβ-injected, and Aβ injection followed by cranial X-irradiation and 
only cranial X-irradiated. Anesthetized animals received 5 µl synthetic Aβ peptide injection with a 10 µl Hamilton microsyringe with the needle kept 
in place for a period of 2min following injection. Sham-operated group received 5 µl of bidistilled water instead of Aβ peptide. Animals were treated 
6 weeks post-surgery with fractionated radiation of 2Gy for 5 days. Neurobehavior studies were undertaken to confirm memory impairment along 
with biochemical indices involved in the antioxidant defense system.
Results: Fractionated cranial X-irradiation proved effective in restoration of activity of enzymes involved in the antioxidant defense system; the 
lipid peroxidation and catalase levels that showed a significant increase in Aβ-treated group decreased on subsequent X-irradiation. Moreover, the 
decrease in the superoxide dismutase, glutathione, glutathione-S-transferase, and glutathione reductase levels witnessed an increase post-irradiation, 
implicating the X-irradiation to be an effective intervention to restore the redox status of the oxidatively stressed brain cells in AD condition.
Conclusion: The present study evaluated the therapeutic potential of low dose fractionated cranial X- irradiation by mitigating the amyloid-induced 
oxidative stress suggesting a novel treatment for AD-associated pathologies.
Keywords: Fractionated X-irradiation, Oxidative stress, Neurodegeneration.
INTRODUCTION
Alzheimer’s disease (AD) is an accelerating public health problem 
worldwide. As the percentage of the population over the age of 65 years 
increases, the prevalence of the disease is anticipated to increase 
proportionately, making the treatment of AD a major health priority [1]. 
Clinical manifestations include progressive impairments in visuospatial 
perceptions, memory, calculations, and behavior inevitably affecting 
all intellectual functions leading to a complete dependence for basic 
functions of daily life, and premature death [2].
In 1906, a German physician pioneered to describe the pathologic 
abnormalities in the autopsied brain of a woman who was affected 
for years by memory impairment and progressive loss of cognitive 
function [3]. He reported the presence of a collection of dense deposits 
or plaques outside the neurons and bands of fibers or tangles within 
the brain cells [4]. These extracellular senile plaques and intracellular 
neurofibrillary tangles of tau have been recognized to be the two core 
pathological hallmarks that define the AD.
The senile plaques as described by Alzheimer were isolated by 
Glenner and Wong in 1984 are composed of amyloid-beta (Aβ), a 
proteolytic fragment of amyloid precursor protein (APP). APP is an 
integral membrane glycoprotein expressed in all tissues and undergoes 
cleavage to release the secretory form (sAPP) and subsequent cleavage 
by ϒ-secretase to release 38–42 amino acids long Aβ peptide [5,6]. 
However, two variants, Aβ1–40 and Aβ1–42, which differ at the carboxyl 
terminus are the predominant plaque proteins found in the blood and 
cerebrospinal fluid at nanomolar levels [7]. The other hallmark feature 
of AD brains - neurofibrillary tangles are composed primarily of Tau, a 
microtubule-associated protein which has extensively been investigated 
as a biomarker. In AD, Aβ fibril induces tau hyperphosphorylation 
at many sites and enzyme-linked immunosorbent assays have been 
developed to recognize various phosphorylated epitopes such as 
threonine 181 and 231 and serine 199, 235, 396, and 404 [8]. As 
a result of this aberrant phosphorylation, tau is unable to bind 
and stabilize microtubules, possibly leading to axon degeneration 
and fibrillary accumulation in the cytoplasm, neutrophil threads, and 
dystrophic neuritis [9]. The AD pathologies (plaques and tangles) are 
found predominantly in the frontal and temporal lobes, including the 
hippocampus. In more advanced cases, the pathology extends to other 
areas of the cortex, including the parietal and occipital regions leading 
to cell death and global reduction in cholinergic activity and other 
important neurotransmitters too [10,11].
Low dose fractionated radiation therapy plays an important role in the 
complex management of primary and secondary brain tumors and has 
been used therapeutically in both malignant and benign conditions 
in multiple organ sites, including symptomatic amyloidosis. However, 
the neuroprotective potential of low dose fractionated therapy is still 
underexplored. Since the pathophysiology of the disease is largely linked 
to the build of the Aβ in the brain, radiation therapy has demonstrated 
a 50–80% reduction in Aβ plaques in both the hippocampus and cortex 
of transgenic murine models in an exclusive study conducted by Wilson 
and Marples 2016 [12].
Knowing that the conventional pharmacologic interventions target 
symptoms but fall short of addressing underlying contributing factors 
for AD, the need to investigate an entirely novel strategy to treat AD 
pathologies is absolutely crucial. Hence, to alleviate the sufferings of 
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this neurodegenerative disorder of such a high global prevalence, this 
innovative study seeks to investigate the low dose fractionated cranial 
X-irradiation induced therapeutic effects on Aβ based models of AD.
METHODS
Animals
Healthy female Sprague Dawley (S.D.) rats weighing 180–220 g were 
procured from the Central Animal House of the Panjab University, 
Chandigarh. Animals were acclimatized to laboratory conditions before 
experimentation and were housed in polypropylene cages under a 
hygienic bed of husk in a well-ventilated departmental animal house. 
The animals were maintained on a standard laboratory pelleted feed 
(Ashirwaad Industries, Tirpari, and Punjab) and water ad libitum 
throughout the period of experimentation. All the procedures on rats 
were done in accordance with ethical guidelines for care and use of 
laboratory animals, which were approved, by Institutional Animal 
Ethics Committee, Panjab University Chandigarh, India.
Experimental sessions were conducted by randomly dividing animals 
into four groups Group 1: Sham-operated, Group 2: Aβ injected, 
Group 3: Aβ injection followed by cranial X-irradiation, and Group 4: 
Only cranial X-irradiated (radiation control).
Chemicals
Aβ (1–40) was purchased from Sigma (St. Louis. MO). Other chemicals 
were purchased from Sigma (St. Louis, USA), Merck, Sisco Research 
Laboratories Pvt., Ltd., (Mumbai, India) and HiMedia Chemicals. The 
Allengers Medical Systems Ltd., USA, provided the X-ray machine for 
the experiments to be conducted.
Surgical procedure
The rats were anesthetized intraperitoneally with sodium thiopentone 
(45 mg/kg i.p.) and placed in a stereotaxic instrument. The scalp was 
incised and drilled at stereotaxically defined lateral cerebral ventricle 
points (1.2 mm behind the bregma, 2 mm meta, and 4 mm deep) [13]. 
Anesthetized animals of Group 2 and Group 3 received 5 µl synthetic Aβ 
(1–40) peptide injection with a 10 µl Hamilton microsyringe with the 
needle kept in place for a period of 2 min following injection.
Animals of the Group 3 were subjected to 10Gy X-irradiation 
(fractionated dose, 2 Gy × 5 days) 4–5 weeks post-intracerebroventricular 
administration of the peptide. The radiation control group (Group 4) was 
also be subjected to a similar dose of X-irradiation, and the sham-operated 
rats (Group 1) received only the vehicle solution (bidistilled water).
Biochemical assays
Animals were sacrificed by decapitation after anesthetization with 
diethyl ether. The brains were immediately removed and rinsed with ice 
cold isotonic saline. Tissue homogenates (20% w/v) were prepared in 
ice-cold 10 mM PBS (pH 7.4). Homogenates were centrifuged at 1000 g 
for 10 min at 4°C. Pellets were discarded, and the supernatants were 
used to determine the reduced glutathione (GSH) and lipid peroxidation 
(LPO) levels. The supernatants were further re-centrifuged at 10,000 g 
for 30 min at 4°C to obtain post-mitochondrial fraction used for the rest 
of the biochemical estimations.
LPO
The quantitative measurement of LPO was done according to the 
method of Wills [14]. Brain homogenates were mixed with ice cold 10% 
trichloroacetic acid (TCA) and were centrifuged at 800 g for 10 min. 
To the supernatant, 0.67% thiobarbituric acid (TBA) was added, and 
the pink color developed by boiling at 100°C was read at 532 nm 
using UV visible spectrophotometer. Since malondialdehyde (MDA) is 
a degradation product of peroxidized lipids, the development of pink 
color with the absorption characteristics (maximum at 532 nm) as TBA-
MDA chromophore has been taken as an index of LPO. The results were 
expressed as nanomoles of MDA per milligram of protein. The amount 
of MDA formed was calculated on the basis of the molar extinction 
coefficient of MDA-TBA chromophore (1.56 × 105/M/cm).
Superoxide dismutase (SOD)
The assay was performed according to the method of Kono, 1978 [15]. 
The assay of SOD is based on the inhibition of the formation of NADH-
phenazine methosulfate - nitroblue tetrazolium (NBT) formazan. 
The reduction of NBT to blue formazon mediated by hydroxylamine 
hydrochloride was determined under aerobic conditions. Addition of 
SOD inhibits the reduction of NBT by superoxide anions generated 
by photo-oxidation of hydroxylamine hydrochloride, and the extent 
of inhibition was taken as a measure of enzyme activity. The reaction 
mixture contained 1.3 mL of 50 mM sodium carbonate solution in 
0.1 mM ethylenediaminetetraacetic acid, 0.5 mL of 96μM NBT, and 
0.1 mL of 0.6% Triton X–100. The reaction was initiated by the addition 
of 0.1 mL of 20 mM hydroxylamine hydrochloride (pH 5.0), and an 
appropriate amount of tissue homogenate and the rate of NBT reduction 
was measured by a spectrophotometer. The activity of the enzyme was 
expressed as international unit/mg protein, where one unit of enzyme 
is the amount of enzyme-inhibiting the rate of reaction by 50%.
Catalase
Catalase was spectrophotometrically determined using the method 
described by Catalase [16]. Briefly, 3 ml reaction mixture in a sample 
cuvette contained 50 mM potassium phosphate buffer (pH 7.0), H2O2 
at a concentration where it shows an optical absorbance of 0.5, and the 
brain homogenate. Every sample was analyzed simultaneously with 
appropriate blanks without H2O2. The decrease in absorbance on the 
decomposition of H2O2 was measured at 240 nm on a double beam 
spectrophotometer.
The amount of H2O2 decomposed was calculated on the basis of the 
molar extinction coefficient of H2O2 (0.0394/M/cm), and the results 
were expressed as μmoles of H2O2 decomposed/min/mg protein.
Glutathione reductase (GR)
GR is a flavoprotein that catalyzes the NADPH-dependent reduction of 
glutathione disulfide (GSSG) to reduced GSH. The utilization of NADPH 
is directly related to the activity of GR. The assay was performed by the 
method of Carlberg and Mannervik (1985) wherein phosphate buffer 
(0.2 M), NADPH and GSSG were added to the cuvette directly [17]. The 
reaction was initiated by the addition of sample, and the decrease in 
absorbance was followed for 2 min at 340 nm. A unit of GR activity is 
defined as the amount of enzyme that catalyzes the oxidation of 1 µM 
NADPH/min/mg protein.
6.22 × 10−3/mM/cm is taken as the molar absorption coefficient of 
NADPH.
Total glutathione (TG)
The TG content was measured following the method of Zahler and 
Cleland [18]. The method is based on the principle of reduction with 
dithioerythritol and determination of the resulting monothiols with 
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) in the presence of arsenite. 
The disulfide in the sample was mixed with dithioerythritol, and the 
reduction is allowed to proceed for 20 min. After reduction, tris buffer 
and sodium arsenite were mixed followed by the addition of DTNB 
(prepared in sodium acetate) and the absorbance is recorded for 3 min. 
The TG contents were expressed in terms of µmoles of GSH/mg tissue. 
Oxidized GSH was quantitated by subtracting the value of GSH reduced 
from TG.
Reduced GSH
Reduced GSH is a non-protein sulfhydryl compound estimated by the 
method of Ellman in which DTNB, a disulfide compound is readily 
reduced by sulfhydryl compounds to release nitromercaptobenzoic 
acid anion that yields an intense yellow color to be read at 412 nm [19]. 
Briefly, 0.1 ml of TCA (25%) was added to tissue homogenate (500 µl) 
and centrifuged at 2000 g for 15 min. The supernatant obtained was 
further diluted with 0.2 M PBS (pH 8.0) and mixed with freshly 
prepared 10 mM DTNB made in 0.2 M phosphate buffer (pH 8.0). The 
optical density of the yellow colored complex formed by the reaction 
of GSH and DTNB (Ellman’s reaction) was measured on a double beam 
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spectrophotometer at 412 nm against a reference that contained 25% 
TCA instead of the sample.
Molar absorption coefficient of GSH 13.6/M/cm.
Glutathione-S-transferase (GST)
GST activity was determined using the method of Habig et al. [20]. 
GST catalyzes the formation of GSH conjugates of 1-chloro-2,4-
dinitrobenzene,1,2-dichloro-4-nitrobenzene (CDNB), which absorb 
maximum at 340 nm and has an extinction coefficient of 9.6/mM/cm. 
The assay involved the use of CDNB as a substrate for GST. The tissue 
homogenate was added to the reaction mixture consisting of sodium 
phosphate buffer (100 mM and pH 6.5), CDNB and GSH and the 
absorbance was recorded at 340 nm for 3 min. The activity was 
expressed as μmol CDNB conjugate/min/mg protein using an extinction 
coefficient of 9.6/mM/cm.
Protein estimation
Protein contents were estimated using the method of Lowry et al. [21].
Statistical analysis
The statistical significance of the data was determined using one-way 
analysis of variance (ANOVA) and a multiple post-hoc tests (Student 
Newman–Keuls). The results were represented as mean ± S.D of six 
observations. The comparisons were made as follows:
*p≤0.05, **p≤0.01, and ***p≤0.001 by Newman–Keuls test when the 
values are compared to the sham control group.
#p≤0.05, ##p≤0.01, and###p≤0.001 by Newman–Keuls test when the 
values are compared to Group II.
RESULTS
LPO
Intracerebroventricular administration of Aβ caused a statistically 
significant increase in the levels of LPO as compared to the sham control 
animals (Table 1). Fractionated X-irradiation brought a decrease in 
the MDA levels indicative of its normalization whereas no significant 
change in LPO levels was observed in the radiation control rats as 
compared to the sham control.
SOD and catalase
An increase in the activity of CAT was observed in the cerebral 
cortex of the amyloid injected rats as compared to the sham control 
group. However, X-irradiation to the amyloid treated rats was able to 
significantly reduce the elevated catalase levels. On the contrary, SOD 
levels significantly decreased in the amyloid injected rats that restored 
its level in the group that was subsequently treated with X-rays 
(Table 2).
GSH system
The reduced GSH levels, the GST activity, and the GR levels were 
significantly decreased in the cortex of the amyloid injected rats when 
compared with the control group. However, the TG content was found 
to increase in the amyloid treated group whereas with X-irradiation the 
levels attenuated significantly (Tables 3 and 4).
DISCUSSION
A number of molecular and cellular events have been implicated in the 
initiation and development of an AD, oxidative stress to playing a crucial 
role in its pathogenesis [22,23]. Brain is more vulnerable to oxidative 
damage than all other organs due to high levels of polyunsaturated fatty 
acids and high oxygen utilization [23]. High levels of Aβ induce oxidative 
stress impairing cellular ion homeostasis that renders excitotoxicity to 
neurons eventually leading to apoptosis [24]. In our experimental study, 
we observed amplified LPO levels with the administration of Aβ. LPO is 
a self propogative process of oxidative degradation of polyunsaturated 
fatty acids in biological membranes leading to disruption of their 
structure and functions. Intracerebroventricular administration of Aβ 
led to a significant elevation of MDA as compared to control animals 
possibly due to the interaction of reactive oxygen species with the 
membrane lipids, membrane-bound proteins and eventually affecting 
the activity of ion channels too. A significant elevation in the levels 
of 4-hydroxynonal has been reported in the cortex, amygdala, and 
hippocampal regions of the AD brains [25]. Aβ has also been shown to 
stimulate ROS production and LPO in primary cortical neurons [26,27]. 
However, the levels of MDA decreased post low dose fractionated 
X-irradiation suggesting its neuroprotective role. The decrease may be 
attributed to free radicals scavenging in the cells that further inhibit 
peroxidation of the labile unsaturated fatty acids leading to membrane 
stabilization [28].
GSH is a ubiquitous tripeptide, which due to its thiol group in the 
cysteine residue plays a crucial role in detoxification of reactive oxygen 
species and peroxides either by directly interacting with reactive 
oxygen/nitrogen species or indirectly by working as a cofactor for 
various enzymes [28-31]. Thus, depletion in the levels of GSH under 
oxidative stress induced by Aβ administration suggests consumption of 
GSH to neutralize free radicals produced by increased LPO [32].
The oxidized and reduced forms of GSH (GSSG and GSH) act together 
to maintain the redox status of the cell [30]. GR uses NADPH as the 
electron source to convert GSSG to GSH, which gets oxidized back to 
GSSG by the action of GST. As a consequence of GSH depletion post Aβ 
treatment, a decline in GST activity was also observed as GSH serves as 
a substrate for GST and the lack of substrate brought down the levels 
of GST too. However, a significant rise in the enzymatic activity of GST 
and intracellular stores of GSH post-X-irradiation suggests a decrease 
in the oxidative injury of the brain cells. Moreover, a decrease in the 
GR levels of the brain induced by amyloid also justifies the decrease 
in GSH content of the cell and further confirms our findings. Further, 
under oxidative stress conditions, with depletion in the GSH levels, 
a concomitant increase in the GSSG (oxidized GSH) level occurs 
disbalancing the GSH: GSSG ratio thereby increasing the TG levels of the 
oxidatively stressed brain cells in AD condition [33].
Specific antioxidant enzyme activity of SOD was found to decrease 
significantly post-intracerebroventricular administration of amyloid. 
The metalloenzyme, SOD is the primary scavenger of superoxide 
anion [34,35], the synthesis of which is stimulated by the production 
of ROS [36]. SOD inhibits OH− production by scavenging O2− thus 
converting the superoxide anion to oxygen and hydrogen peroxide [37] 
and hence it can be postulated that the decrease in enzyme activity 
is presumably in advanced stages of peroxidation where the enzyme 
becomes depleted and thus unable to scavenge the free radicals in the 
cells [38]. The X-irradiation post-Aβ administration tends to normalize 
the SOD levels indicative of triggering the body’s antioxidant defense 
system. However, the increase in catalase activity that reduced to 
near control levels after fractionated radiation treatment suggests 
the increase in enzyme activity to combat the adverse effects of the 
increased free radicals due to the amyloid-induced neurotoxicity. The 
Table 1: Effect of fractionated low dose X-irradiation on LPO 
levels in the cerebral cortex of rat brain subjected to Aβ 
treatment
Group LPO 





*p≤0.05, **p≤0.01, and ***p≤0.001 by Newman–Keuls test when the values 
are compared to Sham control group. #p≤0.05, ##p≤0.01, and ###p≤0.001 
by Newman–Keuls test when the values are compared to Aβ group. 
Aβ: Amyloid-beta, MDA: Malondialdehyde, LPO: Lipid peroxidation
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possible explanation for the elevated activity of catalase and depressed 
activity of SOD can presumably be due to alteration of the activity of 
transcription factor nuclear factor E2-related factor 2 by ionizing 
radiations which further has an impact on the action of antioxidant 
proteins (such as SOD and glutathione peroxidase) and free radical 
scavenging enzymes [39,40].
CONCLUSION
The present study evaluated the therapeutic potential of low dose 
fractionated cranial X-irradiation by mitigating the Aβ-induced oxidative 
stress suggesting a novel treatment for AD-associated pathologies.
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